At SEB"s Nordic Seminar, Curasight highlighted its recent partnership with Curium in prostate cancer with uTRACE as an important milestone and said that a potential FDA filing should be expected in 2027. More interesting though was a promise to accelerate the theranostics platform in 2024, especially pushing uTREAT further ahead on its clinical development phases; the company could not give precise information on which indication, but our feeling is within brain cancer.

Länk till analysen